Related Experiment Video

Updated: Apr 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Gefitinib causes growth arrest and inhibition of metastasis in human chondrosarcoma cells

Jian Song1, Jiaxue Zhu, Qiang Zhao

  • 1Department of Orthopaedics, Shandong Jining No.1 People's Hospital, 6 Jiankang Road, Jining, Shandong, 272000, China.

Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|July 28, 2015
PubMed
Abstract

Insights

Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, significantly reduced chondrosarcoma cell growth and metastasis. This study suggests gefitinib may be a promising treatment for chondrosarcoma proliferation and spread.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Chondrosarcomas are malignant bone tumors resistant to conventional therapies.
  • The epidermal growth factor receptor (EGFR) pathway is implicated in various cancers.
  • The role of EGFR inhibitors in chondrosarcoma is not well understood.

Purpose of the Study:

  • To investigate the expression of EGFR in human chondrosarcoma cell lines.
  • To evaluate the effects of the EGFR inhibitor gefitinib on chondrosarcoma cell proliferation and metastasis.

Main Methods:

  • Analyzed EGFR protein expression in three human chondrosarcoma cell lines.
  • Assessed gefitinib's impact on cell proliferation (MTS assay), cell cycle (flow cytometry), and migration (migration assays).
  • Evaluated metastasis-related protein expression (bFGF, MMP-2, MMP-9) via western blotting.

Main Results:

  • All tested chondrosarcoma cell lines expressed EGFR protein.
  • Gefitinib significantly inhibited cell growth and induced cell cycle arrest.
  • Gefitinib reduced migration and downregulated metastasis-related proteins (bFGF, MMP-2, MMP-9).

Conclusions:

  • Gefitinib effectively inhibits chondrosarcoma cell proliferation and metastatic potential.
  • Findings suggest gefitinib may be a potential therapeutic agent for chondrosarcoma.
  • Understanding gefitinib's mechanism can advance chondrosarcoma treatment strategies.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.8K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K